药物包衣技术进展

介绍了目前药物表面包衣的方法、材料及影响因素,主要介绍了流化床法和锅包衣法,阐述了不同包衣方法的特点,对包衣技术的发展趋势进行了展望。     

关于构建我国药品不良反应保险救济机制问题的研究

2006年上海试点的“严重药品不良反应综合保险”初探市场,未能实现药企蜂拥而至的期望局面,而是十分落寂地收场。药品不良反应保险救济机制一直未能实现,已成为我国医药业一大难题。本文通过对药品不良反应定义的分析,探析了我国建立药品不良反应保险救济机制的可行性,再结合近期的“严重药品不良反应综合保险”的失败经验,提出了完善救济制度、累积相关数据、建立鉴定委员会、政府补贴并强制购买等相关的政策与建议。     

中、美医药领域价值工程应用进展研究

目的加快价值工程在新药研发中的应用,降低新药研发成长,从而控制医疗费用的不断上涨。方法研究中、美两国价值工程在医药领域的发展现状,分析目前其在我国医药领域应用的困难及现实必然性。结果与结论针对现状,建议在政策规定、价值文化等方面要加强建设,为价值工程在我国医药领域的发展做好充分准备。     

新上市专利药的定价方法

目的为完善我国新上市专利药品价格管理提供参考,特研究新上市专利药品定价方法。方法总结我国现阶段专利药品价格管理方式,讨论不足之处。结果与讨论提出药物经济学定价的方法。     

Information Contents in Japanese OTC Drug Advertising from Elaboration Likelihood Model Perspective: Content Analysis of TV Commercials and OTC Drug Websites

Based on the Elaboration Likelihood Model, the current study investigates information types that are cross-promoted in Japanese pharmaceutical advertising. The results from a quantitative content analysis of OTC drug brands' TV commercials broadcasted in Japan between 2014 and 2015 and their corresponding product websites (n = 150) show that Japanese OTC drug promotions feature more informational cues in the latter; cues such as price, safety, quality, components, and guarantees/warranties are particularly prominent. Furthermore, product websites tend to focus more on rational appeals, whereas TV commercials emphasize emotional appeals. No difference is found between these media types regarding celebrity and noncelebrity endorser usage.     

刍议新医改政策对制药企业药品营销的影响

近年来,我国医药行业有很大发展,消费保持高速增长,但仍然存在制药企业规模小、研发弱、市场集中度低,药品流通领域"多、小、散、乱"等问题。新医改对制药企业的药品销售从产品、价格、渠道和促销等方面都带来影响。制药企业要认真研读此次新医改相关政策和文件,规避新医改政策给企业造成的不利影响,并利用此次医改的时机和国家对医药行业进行结构调整的机会,从战略层面上来研究和寻求对策。     

Exploring the Structure of the Illegal Market for Cannabis

Summary This paper explores the middle and retail levels of the illegal market for cannabis in New Zealand using national household drug survey data. Those who reported purchasing half or full ounces of cannabis were defined as middle level market participants, while those who purchased smaller weights or merely used cannabis were defined as retail level participants. Those who had purchased cannabis were then further categorised as either cannabis ‘buyers’ (i.e. those who only purchased sufficient cannabis for their own consumption needs) or cannabis ‘dealers’ based on whether the surplus of cannabis they had, after their own personal consumption was deducted, exceeded the legal definition of cannabis dealing (i.e. possession of 28 g of cannabis or more). Nine per cent of those who had purchased cannabis in the previous year were categorised as middle level participants with 69% of these defined as middle level dealers and 31% as middle level buyers. Middle level cannabis dealers were projected to earn, on average, $2927 (NZD) net annual profit from selling surplus (rate of return of 34%). There was a wide variation in the projected net earnings of the middle level cannabis dealers with the majority earning only modest incomes (bottom 50% – $260 per year, top 10% – $25000 per year). Participants at all levels of the market commonly reported receiving cannabis for ‘free’ and this is likely to reflect the social sharing of cannabis during group consumption and non-cash payments for cannabis. This barter and gift giving tradition may provide cannabis users with a degree of insulation from any price increases for cannabis brought about by law enforcement activity. Cannabis selling creates a convenient source of income for heavy cannabis users to finance their own personal cannabis consumption, which may also dampen the impact of any rise in price brought about by law enforcement success.The 2003 HBS-Drug Use was funded by the New Zealand Ministry of Health and carried out as part of the Public Health Intelligence (PHI) Health Behaviours Survey Monitor. The statistical design for the 2003 survey was completed by Dr. Megan Pledger at SHORE, and by James L. Reilly from Statistical-Insights. The questionnaire was adapted and extended from the National Drug Survey questionnaire for the Health Behaviours programme by Dr. Chris Wilkins. Data collection was managed by Dr. Chris Wilkins, Rachael Lane, Joe Morley and Mary Blade. The statistical analysis of 2003 HBS-Drug Use was completed by Paul Sweetsur. The analysis in this paper was partly funded by the New Zealand Police.     

我国新药研发领域中技术转移问题的研究

本文分析了新药研发技术转移的一般过程,针对我国新药研发技术转移过程中存在的问题,提出对策与建议。     

Collective livestock research for sustainable disease management in Mali and Burkina Faso

An international multi-disciplinary team of scientists, led by the International Livestock Research Institute (ILRI), tackled the problem of bovine trypanosomosis and the development of drug resistance in West Africa, inter alia, by the promotion of rational drug use (RDU) principles. These principles had been brought to farmers by practical training and by the provision of information leaflets. This study aimed to evaluate the impact of RDU training at smallholder level with respect to advances in farmers' knowledge and farm productivity before research outputs could be scaled up. Therefore, 508 cattle farmers attended a disease-specific knowledge test and provided information about farm production. Results show that farmers who participated in the training are more likely to identify signs and causes of the disease and to correctly administer drugs. Allocating scores to each question in the knowledge tests and scrutinizing the differences between trained and untrained farmers by matching procedures shows that participating farmers reach higher scores in all knowledge categories. Moreover, the acquisition of additional knowledge and the application of improved control strategies significantly increase farm performance. Additionally, an allocative effect was identified since trypanocide expenditures were saved by less expensive inputs.